Mycoplasma Testing Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Mycoplasma Testing Market Trends and Insights

Expansion of Biopharma and Cell & Gene Therapy Manufacturing Facilities

Capacity ramp-ups in autologous and allogeneic therapy plants have multiplied sample volumes that require 100% batch testing. Contamination prevalence in cell cultures ranges between 15% and 35%, and FDA guidance now mandates mycoplasma testing after pooling and prior to washing, increasing sampling frequency.^{[1]American Type Culture Collection, “Cell Culture Contamination Studies,” atcc.org} Continuous perfusion bioreactors raise real-time monitoring needs, pushing demand for automated analyzers that handle higher throughputs with minimal human intervention. Facility roll-outs in emerging markets must complete qualification studies, creating greenfield demand for third-party test services. Together, these trends add 2.8 percentage points to the forecast CAGR.

Regulatory Mandates Require Mycoplasma Release Testing for Biologics

The FDA’s laboratory developed tests rule and EMA guidance for advanced therapy medicinal Products require validated assays from a master cell bank to a finished drug.^{[2]Federal Register Editorial Team, “Laboratory Developed Tests; Final Rule,” federalregister.gov} The European Medicines Agency's guidelines for Advanced Therapy Medicinal Products mandate comprehensive mycoplasma testing throughout the manufacturing process, from master cell banks to final product release. These regulatory changes create non-discretionary demand for testing services, as manufacturers cannot release products without demonstrating mycoplasma absence through validated methods. Compliance spending accelerates through 2027 as phased LDT oversight takes effect.The phased implementation of new LDT regulations over four years creates predictable demand growth as laboratories upgrade their testing capabilities to maintain compliance.

Increasing Incidents of Cell-Culture Contamination

Industry case studies document filtration bypass, DNA persistence, and charge-variant shifts in monoclonal antibodies following undetected contamination.^{[3]Wiley Editors, “Charge Variants in Contaminated mAbs,” onlinelibrary.wiley.com} Economic fallout includes batch destruction, facility shutdowns, and regulatory inspections, prompting proactive screening policies. High-density cultures and longer residence times in intensified processes further elevate risk, translating into more frequent interim tests.

Rising Demand for Rapid, High-Sensitivity PCR-Based Assays

Digital PCR detects ≤10 CFU/mL without reference curves, providing absolute quantification that meets release-testing precision needs. Platforms such as the BIOFIRE Mycoplasma system report results in 60 minutes, condensing lot-release cycles. AI-driven analytics streamline interpretation and cut false positives. Regulatory nods, e.g., Health Canada’s clearance of Roche MycoTOOL, validate these technologies for commercial adoption.

High Capital Expenditure for Implementing Automated Detection Systems

Entry-level automated analyzers cost USD 100,000–500,000, with annual service contracts topping USD 50,000. Smaller CTLs and academic labs struggle to justify such outlays, prolonging reliance on manual culture methods. FDA LDT compliance adds validation costs and strains capital budgets, curbing near-term uptake. Smaller contract testing laboratories face particular challenges in justifying automation investments given their limited sample volumes and diverse testing requirements. The complexity of validating automated systems for regulatory compliance adds significant time and cost burdens, with validation studies typically requiring 6-12 months and specialized expertise. 

False-Positive/-Negative Retest Delays

DNA carry-over and cross-contamination trigger confirmatory workflows that erode the speed advantage of PCR, while false negatives threaten patient safety and invite regulatory scrutiny. Discordant results between culture and molecular assays extend release timelines by weeks, especially when investigation protocols lack standardisation. Regulatory agencies' requirements for investigation of atypical results can delay product releases by weeks or months, particularly when multiple testing methods yield conflicting outcomes. The industry's transition from culture-based to molecular methods introduces new sources of variability that require extensive method validation and comparison studies to establish confidence in results.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product & Service: Outsourced Services Gain Momentum

Kits and reagents maintained a 45.72% share in 2025, underlining their consumable nature within the Mycoplasma testing market. The Services segment is set to expand at 14.15% CAGR as biomanufacturers delegate method validation and routine screening to accredited laboratories. High regulatory hurdles and evolving assay formats encourage companies to buy expert capacity instead of building it. Eurofins’ network of 45+ global sites illustrates how scale produces cost-efficiencies that individual firms cannot replicate.

Automation-ready instruments show steady but slower growth because purchasers often tie them to long-term reagent contracts. The BIOFIRE platform and Rapid Micro Biosystems’ vial-reader appeal by blending speed with pharmacopeial compliance. As services grow, kit vendors align with third-party labs under reagent-rental models that lock in supply revenues. This synergy consolidates buyer–supplier dependencies and drives volume in both categories.

By Technology: Digital PCR Disrupts Legacy Workflows

qPCR holds 63.85% of the 2025 Mycoplasma testing market share thanks to entrenched protocols and broad instrument availability. Digital PCR, with a 15.75% growth rate, mitigates standard-curve errors and detects rare events vital for gene-therapy lots. Sensitivity gains resonate with regulatory auditors seeking robust quantification. Conventional PCR remains a budget choice for legacy facilities, while ELISA and DNA staining stay relevant in niche academic applications. Next-generation sequencing promises multiplex pathogen screens but awaits regulatory consensus.

Regulatory bodies now accept nucleic-acid methods equivalent to culture for release testing, catalysing digital PCR uptake. Instrument makers invest in microfluidic chip formats that slice reaction mixes into thousands of partitions, lowering detection thresholds. AI augmentation further lessens operator skill barriers, unlocking broader lab adoption.

By Application: Gene Therapy Drives Highest Upside

Cell-line quality control dominated the mycoplasma testing market in 2025, with a 41.20% share. Yet gene and cell therapy manufacturing will outpace all other uses at a 17.10% CAGR. Extended culture durations, autologous workflows, and multi-step manipulations amplify contamination risk, compelling frequent in-process checks. Regulatory guidance treats each manufacturing step as a potential contamination window, swelling sample numbers.

Bioproduction batch-release testing remains a staple, while raw-material & media testing gains share as firms recognise upstream vectors such as animal-origin components. Vaccine and virus manufacturers broaden surveillance alongside rising viral-vector therapeutics pipelines. Academic discovery work sits outside stringent release rules but still demands periodic screening to protect research integrity.

By End User: CMOs Capture Outsourcing Wave

Biopharma and biotechnology Companies accounted for 64.70% of the end-user segment in 2025, yet CMOs will grow the fastest at 14.98% CAGR as virtual biotech firms rely on third parties from plasmid prep through fill-finish. The Mycoplasma testing market size for contract labs widens when projects scale from pre-clinical to commercial runs.

Diagnostic and reference labs diversify into biologics support, chasing higher-margin industry work. Cell banks guard against line cross-contamination because a single tainted master cell bank can invalidate years of submissions. Workforce shortages push even large pharma to outsource surge testing during tech-transfer or facility shutdown periods, reinforcing the CMO growth curve.

Geography Analysis

North America led with 40.25% of 2025 revenue as FDA oversight, mature bioprocessing infrastructure, and early technology adoption underpin stable demand. The region’s biocluster density and capital availability encourage rapid replacement of culture methods with automated PCR systems. Service providers leverage proximity to innovators, enabling just-in-time sample logistics and compliance audits.

Europe follows with a cohesive regulatory framework from the EMA and harmonised pharmacopoeias that facilitate multi-country lot release. The Mycoplasma testing market size tied to EU gene-therapy trials rises as Germany, Spain, and the United Kingdom host GMP facilities. Vendors cater to multi-language documentation and serialization demands, spurring informatics-enabled assay platforms.

Asia-Pacific represents the fastest-growing arena, expanding at 18.10% CAGR. China’s cell-therapy sector benefits from government priority listings, while India’s production-linked incentive schemes attract vaccine exporters. Singapore’s decentralized QC labs shorten turnaround times for regional biologics plants. Fragmented regulations necessitate local validation, favouring global companies that co-locate service hubs.

South America and the Middle East & Africa trail in absolute revenue but offer untapped upside as domestic vaccine programs and biosimilar plants proliferate. Logistics hurdles and limited cold-chain infrastructure slow penetration of rapid PCR devices, yet public-health investments could unlock future orders once training and service networks mature.

Regulatory Landscape

Regulatory requirements for mycoplasma control in biopharmaceutical production are grounded in compendial standards and regulator expectations. In the United States, USP general chapters 63 (Mycoplasma Tests) and 77 (Mycoplasma Nucleic Acid Amplification Tests) are key references for cell-based manufacturing, alongside regulator guidance for biologics and related expectations covering viral safety and contamination control.

In Europe, the European Pharmacopoeia Commission and EDQM updated Ph. Eur. general chapter 2.6.7, which entered into force on April 1, 2026. The revision reinforces acceptance of NAT as standalone methods when product-specific suitability and performance are demonstrated, including sensitivity targets such as LOD <= 10 CFU/mL or < 100 genomic copies/mL for NAT-based approaches that replace culture. It also tightens execution controls, including adding external controls prior to nucleic acid extraction and checking for inhibition, which increases the focus on validated workflows, reference standards, and documentation for inspections and batch disposition.

Market Opportunities and Future Outlook

The revised EP 2.6.7 alignment supports an upgrade path from culture workflows to NAT-based assays used as standalone release tests, provided product-specific suitability and inhibition controls are demonstrated. This expands demand for end-to-end solutions that include extraction controls, inhibition testing, and reference standards tied to the stated LOD requirements (<=10 CFU/mL or <100 genomic copies/mL). Vendors that package assays with genomic copy-based controls and validation support can benefit as QC organizations standardize documentation and acceptance criteria across multi-site manufacturing networks.

Separately, activity around rapid, closed-system testing points to whitespace in faster lot disposition and outsourced validation capacity, particularly for cell and gene therapy operations with frequent in-process testing needs. In April 2026, bioMerieux introduced the BIOFIRE SPOTFIRE molecular testing system for pharmaceutical quality control, with rapid mycoplasma detection in less than 1 hour. In May 2026, Minaris Advanced Therapies expanded rapid mycoplasma detection services by implementing the BIOFIRE platform in GMP workflows. In parallel, Minerva Biolabs updated Venor Mycoplasma PCR, extraction kits, and GC/CFU reference standards to align with the revised EP 2.6.7 requirements, highlighting opportunities for labs to transition methods, run comparability studies, and manage matrix-specific inhibition risks without extending release timelines.